A British Journal of Cancer study reports that TP53 mutations can shape the immune microenvironment in urothelial carcinoma (UC) by pushing CD8+ T cells toward an exhausted, therapy-resistant state. The findings describe how TP53-driven biology biases tumor-infiltrating T cells, altering the tumor immune landscape (TIME) in ways consistent with poorer clinical outcomes. For immuno-oncology programs, this adds a mechanistic bridge between a common tumor suppressor alteration and immune dysfunction. It suggests that TP53 status may be more than a prognostic marker—potentially a determinant of how effectively a therapy can reinvigorate T cell responses. The extract indicates the study is “groundbreaking” but does not provide specific therapy-response comparisons. Still, the immune-exhaustion framing supports the development of combination approaches that address exhaustion pathways or reprogram the TIME in TP53-mutant settings. Teams developing checkpoint or T-cell-focused regimens may use these insights to refine biomarker strategies and select patient subgroups more likely to respond.